for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Carolyn Mulroney, M.D. (ucsd)
Headshot of Carolyn Mulroney
Carolyn Mulroney



This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells in all clinical trials including NCT04450069, A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies.

Official Title

A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001


Patients will be enrolled following either the completion or early termination/discontinuation from Study NCT04450069 or any protocol in which patients were administered CLBR001. Patients will begin the long-term follow-up period regardless of whether they responded to treatment or progressed on treatment. Patients will be followed for up to 15 years post CLBR001 infusion and will continue to be monitored for safety, immunogenicity, and efficacy.


Relapsed/Refractory B-cell Lymphomas Diffuse Large B-Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma (MZL) Mantle Cell Lymphoma (MCL) Small Lymphocytic Lymphoma (SLL) Primary Mediastinal Large B Cell Lymphoma Transformed Follicular Lymphoma CAR-T Cell Therapy Switchable CAR-T Cell Autologous Cell Therapy CD19 Positive Disease Blood Cancer Hematological malignancy Neoplasms CD19 CAR-T Cell Long Term Follow Up (LTFU) Lymphoma Lymphoma, Follicular Lymphoma, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Mantle-Cell Lymphoma, Large B-Cell, Diffuse CLBR001 and SWI019


You can join if…

Open to people ages 18 years and up

  • All patients who received at least one CLBR001 cell dose and have either discontinued early or completed the core treatment protocol or any protocol such as a managed access protocol as applicable.
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

You CAN'T join if...

  • There are no specific exclusion criteria for this study


  • University of California at San Diego
    San Diego California 92093 United States
  • City of Hope National Medical Center
    Duarte California 91010 United States

Lead Scientist at University of California Health

  • Carolyn Mulroney, M.D. (ucsd)
    Co-Investigator on several clinical trials in the Blood and Marrow Transplantation Division: BMTCTN 0402, IRB # 101006, A Phase III Randomized, Multicenter Trial comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as a Graft-Versus-Host Disease (GVHD) Prophylaxis After HLA- Matched, Related Peripheral Blood Stem Cell transplantation. B.A.


accepting new patients by invitation only
Start Date
Completion Date
Calibr, a division of Scripps Research
Phase 1 research study
Study Type
Expecting 36 study participants
Last Updated